Polatuzumab vedotin combined with rituximab-bendamustine immediately before stem cell mobilization in relapsed diffuse large B-cell lymphoma
Sign Up to like & getrecommendations! Published in 2022 at "Annals of Hematology"
DOI: 10.1007/s00277-022-04803-0
Abstract: Dear Editor, We have read with great interest the report by Wang et al. [1] regarding autologous hematopoietic stem cell transplantation (ASCT) following polatuzumab vedotin combined with rituximab-bendamustine (Pola-BR) for relapsed diffuse large B-cell lymphoma… read more here.
Keywords: bendamustine; therapy; pola; cell ... See more keywords
The molecular rationale for the combination of polatuzumab vedotin plus rituximab in diffuse large B‐cell lymphoma
Sign Up to like & getrecommendations! Published in 2022 at "British Journal of Haematology"
DOI: 10.1111/bjh.18341
Abstract: Polatuzumab vedotin (Pola) is an antibody–drug conjugate that targets the B‐cell antigen CD79b and delivers monomethyl auristatin E (MMAE). It is approved in combination with bendamustine and rituximab (Rit) for relapsed/refractory diffuse large B‐cell lymphoma… read more here.
Keywords: rationale combination; combination; rit; pola ... See more keywords
Phase 2 Trial (POLA Study) of Lurbinectedin plus Olaparib in Patients with Advanced Solid Tumors: Results of Efficacy, Tolerability, and the Translational Study
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers14040915
Abstract: Simple Summary Genomic instability (GI) is a transversal phenomenon in oncology, constituting a hallmark of cancer. In gynecological malignancies, the predictive value of GI has been described and is mainly caused by alterations in the… read more here.
Keywords: lurbinectedin plus; trial; plus olaparib; pola ... See more keywords